vs

Side-by-side financial comparison of GERON CORP (GERN) and P10, Inc. (PX). Click either name above to swap in a different company.

P10, Inc. is the larger business by last-quarter revenue ($81.0M vs $47.2M, roughly 1.7× GERON CORP). P10, Inc. runs the higher net margin — 11.7% vs -39.0%, a 50.7% gap on every dollar of revenue. On growth, GERON CORP posted the faster year-over-year revenue change (67.1% vs -4.7%). Over the past eight quarters, GERON CORP's revenue compounded faster (1597.0% CAGR vs 10.7%).

Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.

P10, Inc. is a global alternative investment management firm that offers a diversified portfolio of investment solutions spanning private equity, private credit, real assets and venture capital. It primarily caters to institutional clients including pension funds, endowments, foundations, and high-net-worth individuals across North America, Europe, and Asia Pacific.

GERN vs PX — Head-to-Head

Bigger by revenue
PX
PX
1.7× larger
PX
$81.0M
$47.2M
GERN
Growing faster (revenue YoY)
GERN
GERN
+71.7% gap
GERN
67.1%
-4.7%
PX
Higher net margin
PX
PX
50.7% more per $
PX
11.7%
-39.0%
GERN
Faster 2-yr revenue CAGR
GERN
GERN
Annualised
GERN
1597.0%
10.7%
PX

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
GERN
GERN
PX
PX
Revenue
$47.2M
$81.0M
Net Profit
$-18.4M
$9.5M
Gross Margin
Operating Margin
-29.4%
31.9%
Net Margin
-39.0%
11.7%
Revenue YoY
67.1%
-4.7%
Net Profit YoY
30.3%
79.0%
EPS (diluted)
$-0.03
$0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GERN
GERN
PX
PX
Q4 25
$81.0M
Q3 25
$47.2M
$75.9M
Q2 25
$49.0M
$72.7M
Q1 25
$39.6M
$67.7M
Q4 24
$85.0M
Q3 24
$28.3M
$74.2M
Q2 24
$882.0K
$71.1M
Q1 24
$304.0K
$66.1M
Net Profit
GERN
GERN
PX
PX
Q4 25
$9.5M
Q3 25
$-18.4M
$2.1M
Q2 25
$-16.4M
$3.4M
Q1 25
$-19.8M
$4.5M
Q4 24
$5.3M
Q3 24
$-26.4M
$1.4M
Q2 24
$-67.4M
$7.0M
Q1 24
$-55.4M
$5.0M
Operating Margin
GERN
GERN
PX
PX
Q4 25
31.9%
Q3 25
-29.4%
14.1%
Q2 25
-25.4%
24.4%
Q1 25
-42.2%
16.6%
Q4 24
26.9%
Q3 24
-99.8%
11.9%
Q2 24
-7860.9%
23.7%
Q1 24
-18465.1%
18.3%
Net Margin
GERN
GERN
PX
PX
Q4 25
11.7%
Q3 25
-39.0%
2.8%
Q2 25
-33.4%
4.7%
Q1 25
-50.1%
6.7%
Q4 24
6.2%
Q3 24
-93.5%
1.9%
Q2 24
-7639.8%
9.8%
Q1 24
-18220.4%
7.6%
EPS (diluted)
GERN
GERN
PX
PX
Q4 25
$0.08
Q3 25
$-0.03
$0.02
Q2 25
$-0.02
$0.03
Q1 25
$-0.03
$0.04
Q4 24
$0.05
Q3 24
$-0.04
$0.01
Q2 24
$-0.10
$0.06
Q1 24
$-0.09
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GERN
GERN
PX
PX
Cash + ST InvestmentsLiquidity on hand
$78.1M
$28.2M
Total DebtLower is stronger
$373.2M
Stockholders' EquityBook value
$248.7M
$403.5M
Total Assets
$567.4M
$928.3M
Debt / EquityLower = less leverage
0.93×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GERN
GERN
PX
PX
Q4 25
$28.2M
Q3 25
$78.1M
$40.0M
Q2 25
$77.7M
$33.4M
Q1 25
$83.7M
$74.4M
Q4 24
$67.5M
Q3 24
$60.3M
$61.5M
Q2 24
$116.9M
$31.2M
Q1 24
$189.8M
$29.0M
Total Debt
GERN
GERN
PX
PX
Q4 25
$373.2M
Q3 25
$393.4M
Q2 25
$373.0M
Q1 25
$357.2M
Q4 24
$319.8M
Q3 24
$319.4M
Q2 24
$300.6M
Q1 24
$314.0M
Stockholders' Equity
GERN
GERN
PX
PX
Q4 25
$403.5M
Q3 25
$248.7M
$396.8M
Q2 25
$259.5M
$388.9M
Q1 25
$268.2M
$374.3M
Q4 24
$386.9M
Q3 24
$292.3M
$394.1M
Q2 24
$306.7M
$396.9M
Q1 24
$344.9M
$400.1M
Total Assets
GERN
GERN
PX
PX
Q4 25
$928.3M
Q3 25
$567.4M
$936.0M
Q2 25
$555.2M
$932.2M
Q1 25
$562.5M
$877.4M
Q4 24
$869.3M
Q3 24
$444.9M
$857.0M
Q2 24
$449.4M
$823.2M
Q1 24
$482.1M
$832.8M
Debt / Equity
GERN
GERN
PX
PX
Q4 25
0.93×
Q3 25
0.99×
Q2 25
0.96×
Q1 25
0.95×
Q4 24
0.83×
Q3 24
0.81×
Q2 24
0.76×
Q1 24
0.78×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GERN
GERN
PX
PX
Operating Cash FlowLast quarter
$-13.6M
$23.0M
Free Cash FlowOCF − Capex
$18.1M
FCF MarginFCF / Revenue
22.3%
Capex IntensityCapex / Revenue
6.0%
Cash ConversionOCF / Net Profit
2.43×
TTM Free Cash FlowTrailing 4 quarters
$14.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GERN
GERN
PX
PX
Q4 25
$23.0M
Q3 25
$-13.6M
$-8.6M
Q2 25
$-27.4M
$13.4M
Q1 25
$-48.0M
$-4.7M
Q4 24
$101.0M
Q3 24
$-58.9M
$27.5M
Q2 24
$-53.5M
$34.8M
Q1 24
$-62.3M
$11.0M
Free Cash Flow
GERN
GERN
PX
PX
Q4 25
$18.1M
Q3 25
$-9.5M
Q2 25
$11.6M
Q1 25
$-6.0M
Q4 24
$96.6M
Q3 24
$25.2M
Q2 24
$-53.7M
$33.9M
Q1 24
$-62.9M
$10.7M
FCF Margin
GERN
GERN
PX
PX
Q4 25
22.3%
Q3 25
-12.6%
Q2 25
15.9%
Q1 25
-8.9%
Q4 24
113.6%
Q3 24
34.0%
Q2 24
-6086.6%
47.7%
Q1 24
-20680.3%
16.2%
Capex Intensity
GERN
GERN
PX
PX
Q4 25
6.0%
Q3 25
1.2%
Q2 25
2.5%
Q1 25
1.9%
Q4 24
5.2%
Q3 24
0.0%
3.0%
Q2 24
23.4%
1.3%
Q1 24
202.3%
0.4%
Cash Conversion
GERN
GERN
PX
PX
Q4 25
2.43×
Q3 25
-4.01×
Q2 25
3.96×
Q1 25
-1.05×
Q4 24
19.12×
Q3 24
19.54×
Q2 24
4.98×
Q1 24
2.18×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GERN
GERN

Segment breakdown not available.

PX
PX

Management Fees$78.1M96%
Advisory Fees$1.8M2%

Related Comparisons